The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study
-
Published:2024-04
Issue:4
Volume:46
Page:313-321
-
ISSN:0149-2918
-
Container-title:Clinical Therapeutics
-
language:en
-
Short-container-title:Clinical Therapeutics
Author:
Liu Zhiyan,
Xie Qiufen,
Zhao Xia,
Tan Yunlong,
Wang Wenping,
Cao Yu,
Wei Xiaohua,
Mu Guangyan,
Zhang Hanxu,
Zhou Shuang,
Wang Xiaobin,
Cao Ying,
Li Xin,
Chen Song,
Cao Duanwen,
Cui YiminORCID,
Xiang Qian
Reference28 articles.
1. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial;Ordi-Ros;Ann Intern Med,2019
2. Rivaroxaban—metabolism, pharmacologic properties and drug interactions;Kvasnicka;Curr Drug Metab,2017
3. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans;Weinz;Drug Metab Dispos,2009
4. Coadministration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects;Mueck;Br J Clin Pharmacol,2013
5. Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT);Mueck;Blood,2007